Targeting Treg Cells In Situ: Emerging Expansion Strategies for (CD4+CD25+) Regulatory T Cells

被引:13
作者
Shatry, Alwi [1 ]
Chirinos, Jackeline [1 ]
Garin, Michael A. [1 ]
Jones, Monica [1 ]
Levy, Robert B. [1 ]
机构
[1] Univ Miami, Sch Med, Dept Microbiol & Immunol, Miami, FL USA
关键词
In situ manipulation; Treg cells; CD4(+)CD25(+); Expansion strategies; Immune regulation; Marrow allograft resistance; VERSUS-HOST-DISEASE; FOXP3; EXPRESSION; DENDRITIC CELLS; VITRO EXPANSION; INTRAVENOUS IMMUNOGLOBULIN; MONOCLONAL-ANTIBODY; CANCER-PATIENTS; VIVO; IL-2; TOLERANCE;
D O I
10.1016/j.bbmt.2009.06.009
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Recognition of the ability of CD4(+)FoxP3(+) T cells (Treg) to influence the generation of peripheral immune responses has engendered enthusiasm for the development of strategies utilizing these cells to regulate immune responses in clinically important settings including transplantation, autoimmunity and cancer. A number of studies have reported effective regulation utilizing ex-vivo expansion approaches and subsequent transfer of Treg populations in experimental models. This commentary discusses recently emerging strategies to activate and expand Treg cells in situ which include antibodies, antigen presenting cells and the use of IL2/anti-IL2 antibody complex. The development of reagents which can stimulate and/or remove Treg cells in situ would represent an important advance towards facilitating new opportunities to harness this compartment for the augmentation of 'wanted' or suppression of 'unwanted' immune responses. Simultaneous targeting of multiple molecules on Treg cells may ultimately enable more effective control of this regulatory sector.
引用
收藏
页码:1239 / 1243
页数:5
相关论文
共 50 条
[31]   The impact of CD4+CD25+ T cells in the tumor microenvironment of hepatocellular carcinoma [J].
Lee, Wei-Chen ;
Wu, Ting-Jung ;
Chou, Hong-Shiue ;
Yu, Ming-Chin ;
Hsu, Pao-Yueh ;
Hsu, Hsiu-Ying ;
Wang, Chao-Ching .
SURGERY, 2012, 151 (02) :213-222
[32]   Nonclassical CD4+CD49b+ Regulatory T Cells as a Better Alternative to Conventional CD4+CD25+ T Cells To Dampen Arthritis Severity [J].
Vicente, Rita ;
Quentin, Julie ;
Mausset-Bonnefont, Anne-Laure ;
Chuchana, Paul ;
Martire, Delphine ;
Cren, Mailys ;
Jorgensen, Christian ;
Louis-Plence, Pascale .
JOURNAL OF IMMUNOLOGY, 2016, 196 (01) :298-309
[33]   CD4+CD25+regulatory T cells in tumor immunity [J].
Chen, Xin ;
Du, Yong ;
Lin, XiuQing ;
Qian, Yan ;
Zhou, Ting ;
Huang, ZhiMing .
INTERNATIONAL IMMUNOPHARMACOLOGY, 2016, 34 :244-249
[34]   Signal transduction in CD4+CD25+ regulatory T cells:: CD25 and IL-2 [J].
Thornton, AM .
FRONTIERS IN BIOSCIENCE, 2006, 11 :921-927
[35]   Mast cells suppress murine GVHD in a mechanism independent of CD4+CD25+ regulatory T cells [J].
Leveson-Gower, Dennis B. ;
Sega, Emanuela I. ;
Kalesnikoff, Janet ;
Florek, Mareike ;
Pan, Yuqiong ;
Pierini, Antonio ;
Galli, Stephen J. ;
Negrin, Robert S. .
BLOOD, 2013, 122 (22) :3659-3665
[36]   Induction and maintenance of self tolerance: the role of CD4+CD25+ regulatory T cells [J].
Kamalesh K. Bala ;
Kamal D. Moudgil .
Archivum Immunologiae et Therapiae Experimentalis, 2006, 54 :307-321
[37]   Therapy with CD4+CD25+ T regulatory cells - should we be afraid of cancer? [J].
Gliwinski, Mateusz ;
Piotrowska, Magdalena ;
Iwaszkiewicz-Grzes, Dorota ;
Urban-Wojciuk, Zuzanna ;
Trzonkowski, Piotr .
WSPOLCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY, 2019, 23 (01) :1-6
[38]   Induction and maintenance of self tolerance:: the role of CD4+CD25+ regulatory T cells [J].
Bala, Kamalesh K. ;
Moudgil, Kamal D. .
ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS, 2006, 54 (05) :307-321
[39]   Dual effect of CD4+CD25+ regulatory T cells in neurodegeneration:: A dialogue with microglia [J].
Kipnis, J ;
Avidan, H ;
Caspi, RR ;
Schwartz, M .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 :14663-14669
[40]   CD4+CD25+ regulatory T cells in systemic sclerosis and other rheumatic diseases [J].
Michels-van Amelsfort, Jocea M. R. ;
Walter, Gina J. ;
Taams, Leonie S. .
EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2011, 7 (04) :499-514